24/7 Market News Snapshot 30 December, 2024 – Marinus Pharmaceuticals, Inc (NASDAQ:MRNS)

December 30, 2024

DENVER, Colo., 30 December, 2024 (247marketnews.com) – (NASDAQ:MRNS) are discussed in this article.
Marinus Pharmaceuticals, Inc. (MRNS) is experiencing a significant surge in market activity, with pre-market trading reflecting a striking increase of approximately 42.70%, bringing the stock price to $0.530 from the previous close of $0.371. The heightened investor interest is evidenced by a robust trading volume of 5.31 million shares, suggesting optimism surrounding forthcoming developments or a favorable market environment for biotech companies. This upward momentum has positioned MRNS as a focal point for traders aiming to leverage potential gains.

In a transformative move within the biotechnology sector, Marinus Pharmaceuticals has entered into a strategic agreement with Immedica Pharma AB, wherein Immedica plans to acquire Marinus. This acquisition aims to enhance Immedica’s portfolio, particularly in the rare disease sector. The deal involves a cash tender offer, followed by a merger, and is expected to significantly impact both companies’ operational frameworks.

As part of the acquisition, Immedica will obtain global rights to ZTALMY® (ganaxolone) oral suspension, a recently FDA-approved medication designed to treat seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients aged two and older. This addition is set to strengthen Immedica’s market position and facilitate its entry into the North American territory.

The cash tender offer values Marinus at approximately USD 151 million, offering shareholders USD 0.55 per share—well above recent trading prices. This transaction has received unanimous backing from the Marinus Board of Directors and is projected to close in the first quarter of 2025, pending customary approvals. Both CEOs expressed optimism regarding the deal, emphasizing its potential to deliver innovative therapies to underserved patient populations and improve outcomes for those affected by rare neurological disorders.

Related news for (MRNS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.